title: The anti-suicidal potential of buprenorphine: a case report.
abstract: The very strong relationship between suicide, depressive disorders, and substance use disorders is well recognized. Certain pain syndromes are significantly associated with suicide, irrespective of co-occurring medical or psychiatric diagnosis. Chronic pain, depression, substance use disorders, and suicide appear to involve overlapping neural pathways and brain regions that function in the processing of emotional and physical pain, as well as maintaining reward and anti-reward circuitry. In this article, we employ a clinical case to illustrate how various stressors disrupted the balance between pain and opioid-facilitated analgesia. This disruption resulted in excessive use of short-acting opioids to treat pain with ensuing allostatic overload and culmination in chronic suicidal ideation with a suicide attempt. Sublingual buprenorphine was selected to treat the opioid use disorder. We propose that the unique pharmacodynamics of this drug served to stabilize dysregulated neural circuits, neurotransmitters, and neuropeptides, allowing the mitigation of pain, assuaging opioid cravings, easing depression, and resolving suicidal ideation. To our knowledge, this is the first case report to describe the possible anti-suicidal effect of sublingual buprenorphine.
authors.affiliation: University of California, San Francisco San Francisco Veterans Affairs Medical Center, California.
authors.forename: Joan M
authors.initials: JM
authors.lastname: Striebel
authors.affiliation: University of California, San Francisco San Francisco Veterans Affairs Medical Center, California.
authors.forename: Raj K
authors.initials: RK
authors.lastname: Kalapatapu
mesh_terms: D000286:Administration, Sublingual; D000494:Allosteric Regulation; D000701:Analgesics, Opioid / Q000009:adverse effects / Q000627:therapeutic use; D001921:Brain / Q000187:drug effects; D002047:Buprenorphine / Q000627:therapeutic use*; D059350:Chronic Pain / Q000534:rehabilitation; D015897:Comorbidity; D061218:Depressive Disorder, Treatment-Resistant / Q000175:diagnosis / Q000523:psychology / Q000534:rehabilitation*; D004347:Drug Interactions; D005260:Female; D006801:Humans; D008875:Middle Aged; D009292:Narcotic Antagonists / Q000627:therapeutic use*; D009293:Opioid-Related Disorders / Q000534:rehabilitation; D016320:Substance Abuse Treatment Centers; D059020:Suicidal Ideation; D013405:Suicide / Q000523:psychology; D013406:Suicide, Attempted / Q000517:prevention & control / Q000523:psychology; D000092864:Suicide Prevention
chemical_list: D000701:Analgesics, Opioid; D009292:Narcotic Antagonists; D002047:Buprenorphine
keywords: buprenorphine; depression; pain; suicidality
references.citation: Biomed Res Int. 2013;2013:687575
references.pmid: 23986909
references.citation: Prog Neurobiol. 2013 Oct;109:1-27
references.pmid: 23827972
references.citation: J Clin Psychopharmacol. 1995 Feb;15(1):49-57
references.pmid: 7714228
references.citation: Neuropsychopharmacology. 2010 Jan;35(1):217-38
references.pmid: 19710631
references.citation: Neurosci Biobehav Rev. 2012 Nov;36(10):2179-92
references.pmid: 22975446
references.citation: Curr Opin Investig Drugs. 2010 Jan;11(1):63-71
references.pmid: 20047160
references.citation: JAMA Psychiatry. 2013 Jul;70(7):692-7
references.pmid: 23699975
references.citation: Brain Res. 2010 Feb 16;1314:56-73
references.pmid: 19782055
references.citation: Arch Gen Psychiatry. 1997 Jul;54(7):597-606
references.pmid: 9236543
references.citation: Neurosci Biobehav Rev. 2013 Dec;37(10 Pt 2):2597-607
references.pmid: 23988582
references.citation: J Neurochem. 2004 Sep;90(5):1258-68
references.pmid: 15312181
references.citation: Lancet. 1982 Sep 25;2(8300):709
references.pmid: 6126640
references.citation: Environ Health Prev Med. 2008 Sep;13(5):243-56
references.pmid: 19568911
references.citation: J Neurosci. 2008 Jan 9;28(2):407-14
references.pmid: 18184783
references.citation: Psychopharmacology (Berl). 2013 Oct;229(3):435-52
references.pmid: 23836029